Abstract: The inventions provided herein relate to methods, and compositions for increasing neuronal connectivity, neuronal survival and/or axonal growth of a population of neural cells in vitro, ex vivo or in vivo. For in vivo applications, in some embodiments, the methods and compositions described herein can be used to treat cognitive, motor and/or sensory function impairment and/or neurodegeneration in a subject or particularly a human subject {e.g., a human subject who is diagnosed as having, or having a risk, for a neurodegenerative and/or neurological condition such as Alzheimer's disease). Methods for determining a risk for a neurodegenerative condition or disorder, e.g., Alzheimer's disease, in a subject {e.g., a human subject) are also provided herein.

Abstract: Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.

Abstract: One or more embodiments of the invention provide various novel formulations, and tablet dosage forms, comprising losartan that are non-crystalline, stable, and/or otherwise improvements over known losartan formulations. One or more embodiments of the invention further provide methods for preparing the formulation, methods for preparing the tablet dosage form, and to methods of administering the tablet dosage and/or formulation comprising losartan. The losartan-containing formulations may be administered to a user to treat hypertension, and related conditions.

Abstract: Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.

Abstract: A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 ?m to about 1.9 ?m. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 ?m to about 1.9 ?m. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 ?m, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.